Endeavour Silver (NYSE:EXK) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 300 percent increase over losses of $(0.02) per share from the same period last year.
BioVie Announces Completion Of Patient Enrollment In Phase 3 Trial Assessing NE3107 In Alzheimer’s Disease
BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced